BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 27
• 28
• 29
• 30

• Drug Development

  Innovent Releases Results of a Phase 3 Clinical Study of Tafolecimab（IBI306）in Chinese Patients with non- Familial Hypercholesterolemia at the American Heart Association (AHA) Scirntific Sessions 2022

  Innovent Biologics, Inc. announces that the results of a phase 3 clinical study of tafolecimab, a recombinant fully human anti-PCSK-9 monoclonal antibody, in Chinese patients with non-familial hypercholesterolemia were presented at the American Heart Association Scientific Sessions 2022 as an e-poster.

  November 6, 2022

   · 

  10 min read
• Ascletis Announces Poster Presentation of Phase I, Single-Dose Study of ASC43F for NASH at AASLD Annual Meeting 2022

  Ascletis Pharma Inc. announces that the abstract of a Phase I, Single-Dose Study of ASC43F for non-alcoholic steatohepatitis has been reported at The Liver Meeting® 2022 of the American Association for the Study of Liver Diseases as poster presentation.

  November 6, 2022

   · 

  2 min read
• Drug Development

  Hexvix®, A Diagnostic Drug for Bladder Cancer of Asieris, Completed the First Patient Dose in Phase III Trial

  Asieris Pharmaceuticals announced that Hexvix®, a drug used for the diagnosis for bladder cancer, completed the first patient dose in Phase III bridging trial.

  November 6, 2022

   · 

  2 min read